Education
About Us
Working with TipRanks
Follow Us
Spero Therapeutics Inc (SPRO)
NASDAQ:SPRO
SPRO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.51 - $3.22
Previous CloseN/A
Volume61.58K
Average Volume (3M)797.32K
Market Cap
$131.95M
Enterprise Value-$5.06M
Total Cash (Recent Filing)$48.89M
Total Debt (Recent Filing)$3.96M
Price to Earnings (P/E)10.8
Beta2.03
Next Earnings
Nov 17, 2025EPS Estimate
-0.39Last Dividend Ex-Date
Sep 16, 2015Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding55,910,640
10 Day Avg. Volume865,687
30 Day Avg. Volume797,319
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.04
Enterprise Value/Revenue-0.15
Enterprise Value/Gross Profit-0.15
Enterprise Value/Ebitda0.07
Forecast
1Y Price Target
$5.00Price Target Upside111.86% Upside
Rating ConsensusHold
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Financial StabilityCash of $48.9M, along with an upcoming $24M development milestone payment from GSK, should provide coverage for operational expenses.
Regulatory ApprovalThe FDA has indicated that positive results from PIVOT-PO and prior clinical trials would be sufficient to approve tebi for cUTI and limited use in acute pyelonephritis.
Trial ProgressThe Phase 3 trial of tebipenem in cUTI is ongoing, with potential for early trial completion if interim outcomes are favorable.
Bears Say
Financial PerformanceSPRO reported a net loss of $13.9M for the first quarter of 2025.
Product Pipeline'206 has been discontinued.
Spero Therapeutics News
SPRO FAQ
What was Spero Therapeutics Inc’s price range in the past 12 months?
Spero Therapeutics Inc lowest stock price was $0.51 and its highest was $3.22 in the past 12 months.
What is Spero Therapeutics Inc’s market cap?
Spero Therapeutics Inc’s market cap is $131.95M.
When is Spero Therapeutics Inc’s upcoming earnings report date?
Spero Therapeutics Inc’s upcoming earnings report date is Nov 17, 2025 which is in 95 days.
How were Spero Therapeutics Inc’s earnings last quarter?
Spero Therapeutics Inc released its earnings results on Aug 12, 2025. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.38 by $0.35.
Is Spero Therapeutics Inc overvalued?
According to Wall Street analysts Spero Therapeutics Inc’s price is currently Undervalued.
Does Spero Therapeutics Inc pay dividends?
Spero Therapeutics Inc pays a Quarterly dividend of $0.015 which represents an annual dividend yield of N/A. See more information on Spero Therapeutics Inc dividends here
What is Spero Therapeutics Inc’s EPS estimate?
Spero Therapeutics Inc’s EPS estimate is -0.39.
How many shares outstanding does Spero Therapeutics Inc have?
Spero Therapeutics Inc has 55,910,640 shares outstanding.
What happened to Spero Therapeutics Inc’s price movement after its last earnings report?
Spero Therapeutics Inc reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.38. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Spero Therapeutics Inc?
Currently, no hedge funds are holding shares in SPRO
Spero Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.00 (111.86% Upside)
$5.00 (111.86% Upside)
Blogger Sentiment
Bullish
SPRO Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 22.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 9.0%
Last 30 Days ▼ 9.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.94%
12-Months-Change
Fundamentals
Return on Equity
-107.28%
Trailing 12-Months
Asset Growth
-53.66%
Trailing 12-Months
Company Description
Spero Therapeutics Inc
Spero Therapeutics, Inc. (SPRO) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel treatments for bacterial infections, including multi-drug resistant bacterial infections. The company focuses on its proprietary platform in developing a pipeline of therapeutics to address critical unmet medical needs, particularly in the area of gram-negative bacterial infections. Spero's core products include SPR994 (tebipenem HBr), an oral antibiotic candidate for treating complicated urinary tract infections, and SPR720, an oral antibiotic candidate for treating non-tuberculous mycobacterial pulmonary disease.
SPRO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Spero Therapeutics is advancing its tebipenem HBr program with promising potential and strategic partnerships, but faces challenges with its SPR720 trial results and financial performance, including decreased revenue and increased losses.View all SPRO earnings summariesSPRO Stock 12 Month Forecast
Average Price Target
$5.00
▲(111.86% Upside)
Technical Analysis
Dyadic International
―
SCYNEXIS
―
Kala Pharmaceuticals
―
Iterum Therapeutics
―
AN2 Therapeutics, Inc.
―
Ownership Overview
8.30% Insiders
4.17% Mutual Funds
0.13% Other Institutional Investors
83.93% Public Companies and
Individual Investors